Ponatinib (BCR-ABL TKI) + blinatumomab (CD19xCD3 BiTE) improves 24-month EFS vs imatinib-chemo in Ph+ ALL

Ponatinib is a third-generation BCR-ABL tyrosine kinase inhibitor and blinatumomab is a CD19xCD3 bispecific T-cell engager; this Phase 3 GIMEMA ALL2820/LAL2820 trial (NCT04722848) randomized frontline adult Ph+ ALL 2:1 to ponatinib–blinatumomab vs imatinib plus chemotherapy (n=158 vs n=78), with MRD-triggered crossover allowed from control. At median 23.7 months’ follow-up, 24-month event-free survival (primary endpoint) was 86% vs 67% (P<0.001) and survival without measurable residual disease was 68% vs 42%; complete hematologic response at end of induction was 94% vs 79% and molecular response after blinatumomab consolidation was 71% vs 49% (64% molecular response after crossover). Overall survival was closer (90% vs 85%) and relapse incidence favored ponatinib–blinatumomab (5% vs 13%); only 19% of responders in the intervention arm proceeded to transplant—supporting a less transplant-dependent frontline strategy than historical imatinib+chemo pathways (which typically rely more heavily on allogeneic HSCT to deepen molecular remissions).